Progyny Reports Record 2025 Financial Results, Issues Positive 2026 Guidance, and Continues Share Buyback
Summary
Progyny reported record Q4 and full-year 2025 financial results, issued positive guidance for 2026, and highlighted significant progress on its share repurchase program.
Key Events
-
Record 2025 Financial Performance
Progyny achieved record full-year 2025 revenue of $1,288.7 million (up 10% year-over-year), Adjusted EBITDA of $222.1 million (up 12% year-over-year), and operating cash flow of $210.2 million.
-
Positive 2026 Financial Guidance Issued
The company projects full-year 2026 revenue between $1.355 billion and $1.405 billion, reflecting 5.1% to 9.0% growth, and anticipates net income of $95.4 million to $106.1 million, marking its tenth consecutive year of revenue growth.
-
Significant Share Repurchase Program Continues
Progyny repurchased 3.3 million shares for $83.6 million in Q4 2025, bringing the total to approximately 6.5 million shares for $160 million under its $200 million authorization, demonstrating a strong return of capital to shareholders.
Analysis
Progyny, Inc. announced strong financial results for the fourth quarter and full year 2025, achieving record levels in revenue, Adjusted EBITDA, and operating cash flow. The company also provided optimistic financial guidance for 2026, projecting its tenth consecutive year of revenue growth. Furthermore, the ongoing share repurchase program, which has returned approximately $160 million to shareholders to date, signals a commitment to enhancing shareholder value. These factors collectively present a positive outlook for the company's operational performance and capital allocation strategy.
At the time of this filing, PGNY was trading at $21.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.98 to $28.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.